HCID 86592097, 화합물 → HCID 21912710, 화합물
반응식
C(OC([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:15]([C:22]([F:25])([F:24])[F:23])=[N:16][N:17]([CH3:21])[C:18]=2[O:19][CH3:20])[CH2:10][CH2:9]1)=O)(C)(C)C.C(OC(N1CCC(C2C(OC)=NN(C)C=2C(F)(F)F)CC1)=O)(C)(C)C>N1CCCCC1>[CH3:20][O:19][C:18]1[N:17]([CH3:21])[N:16]=[C:15]([C:22]([F:25])([F:23])[F:24])[C:14]=1[CH:11]1[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]1참가 물질
4
실험 절차
The title compound was prepared using conditions similar to those described in Piperidine 35, Step E, substituting 1-(tert-butoxycarbonyl-4-(5-methoxy-1-methyl-3-(trifluoromethyl)-(1H)-pyrazol-4-yl)piperidine (from Piperidine 35, Step D) for 1-(tert-butoxycarbonyl-4-(3-methoxy-1-methyl-5-(trifluoromethyl)-(1H)-pyrazol-4-yl)piperidine. For the title compound: 1H NMR (500 MHz, CD3OD) δ 3.94 (s, 3H), 3.72 (s, 3H), 3.10 (d, J=13, 2), 2.70 (tt, J=13, 4, 1H), 2.64 (td, J=13, 3, 2H), 1.84 (qd, J=13, 4, 2H), 1.71 (d, J=13, 2H); ESI-MS 264.1 (M+H); HPLC A: 1.1 min.